UMI or not UMI, that is the question for scRNA-seq zero-inflation
Published in Nature Biotechnology
Published in Nature Biotechnology
Published in Nature Biotechnology
In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay.
Published in Nature Biotechnology
Following mixed results in the clinic against COVID-19, antibody engineers are further optimizing SARS-CoV-2 antibodies with the aim of improving outcomes.
Published in Nature Biotechnology
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Published in Nature Biotechnology
The new drug not only is a boon for patients with spinal muscular atrophy, but also may spearhead the development of further chemical RNA modulators for a broad range of conditions.
Published in Nature Biotechnology
Immersive virtual reality simulations tailored to aspiring industry operators in biopharma manufacturing could become a cost-effective alternative to real-life training for teaching practical skills.
Published in Nature Biotechnology
Biosimilar manufacturing process patent applications first filed more than a year after the biologic is approved, which represent the largest source of patent assertions in biosimilar litigation, could be addressed without requiring intervention by either the courts or Congress.
Published in Nature Biotechnology
Published in Nature Biotechnology
Published in Nature Biotechnology